365 related articles for article (PubMed ID: 22806877)
21. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
[TBL] [Abstract][Full Text] [Related]
22. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
[TBL] [Abstract][Full Text] [Related]
23. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
24. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC
J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293
[TBL] [Abstract][Full Text] [Related]
25. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
Jang WJ; Jung SK; Kang JS; Jeong JW; Bae MK; Joo SH; Park GH; Kundu JK; Hong YS; Jeong CH
Cancer Sci; 2014 Oct; 105(10):1245-53. PubMed ID: 25117641
[TBL] [Abstract][Full Text] [Related]
27. Heat shock protein 90 inhibitors in non-small-cell lung cancer.
Pillai RN; Ramalingam SS
Curr Opin Oncol; 2014 Mar; 26(2):159-64. PubMed ID: 24463348
[TBL] [Abstract][Full Text] [Related]
28. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
29. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
[TBL] [Abstract][Full Text] [Related]
30. [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
being resistant to EGFR-TKI].
Zhao L; Cao F
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):778-82. PubMed ID: 25404267
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
32. Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells.
Shiraishi N; Onda T; Hayashi K; Onidani K; Watanabe K; Sekikawa S; Shibahara T
Oncol Rep; 2021 Feb; 45(2):448-458. PubMed ID: 33416122
[TBL] [Abstract][Full Text] [Related]
33. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
34. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.
Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Jul; 60(7):E42-5. PubMed ID: 23303741
[TBL] [Abstract][Full Text] [Related]
35. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Giubellino A; Sourbier C; Lee MJ; Scroggins B; Bullova P; Landau M; Ying W; Neckers L; Trepel JB; Pacak K
PLoS One; 2013; 8(2):e56083. PubMed ID: 23457505
[TBL] [Abstract][Full Text] [Related]
36. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
37. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Socinski MA; Goldman J; El-Hariry I; Koczywas M; Vukovic V; Horn L; Paschold E; Salgia R; West H; Sequist LV; Bonomi P; Brahmer J; Chen LC; Sandler A; Belani CP; Webb T; Harper H; Huberman M; Ramalingam S; Wong KK; Teofilovici F; Guo W; Shapiro GI
Clin Cancer Res; 2013 Jun; 19(11):3068-77. PubMed ID: 23553849
[TBL] [Abstract][Full Text] [Related]
38. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M
Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794
[TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
40. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
